Enrolling now · NCT07225829

A study testing whether a GLP-1 medicine from 4Moving Biotech, liraglutide, can ease joint pain.

Who can join: Adults 40 to 80, have knee osteoarthritis (joint pain), BMI 18.5+.
What you take: liraglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts: The study runs about 15 months.
What you get: The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

Phase Phase 2Sponsor 4Moving BiotechDrug liraglutideClass GLP-1 RASites 3 USEnrollment target 129

What this study is for

Full study title: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis.

Primary condition: Knee Osteoarthritis. Also studied in: Synovitis of Knee.

Who can join, in detail

Age 40 to 80

Sex All

BMI 18.5 to 35

Key inclusion criteria

Participants who have the capacity to give informed consent and who are willing to comply with all trial related procedures and assessments.
Participants between 40 and 80 years of age.
Female participant of childbearing potential (defined as any woman unless postmenopausal for at least one year or surgically sterile) must use highly effective methods of contraception as defined in the protocol. Highly effective contraceptive measures must be continued throughout the trial until the final visit.
Bodyweight > 40 kg.
Body mass index (BMI) >= 18.5 and <= 35.

Key exclusion criteria

Pregnant or breastfeeding women.
Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the TK (varus > 10°, valgus > 10°) by radiography.
Secondary OA such as joint dysplasia, aseptic osteonecrosis, joint infection, acromegaly, Paget disease, hemochromatosis, joint crystal disease or any inflammatory joint disease.
Any known active infections including skin infections at the site injection or increased predisposition for the development of infections.
Any partial knee replacement of the TK.

Where this study is enrolling

This trial has 3 US sites across 3 states. Contact the site coordinator directly to start the screening process.

Arizona

Tucson Orthopaedic Institute
Tucson, Arizona
Nebojsa Skrepnik, MD

Illinois

Northwestern University Feinberg School of Medicine
Chicago, Illinois
Thomas Schnitzer, MD

Massachusetts

Skylight Health Research Burlington
Burlington, Massachusetts
Timothy McAlindon, MD

Follow this trial

We email you if NCT07225829 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: 2025-06-17. Expected completion: 2026-09. Last updated on ClinicalTrials.gov: 2026-04-14.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.